SHARON LEVY: Open Payments
NPI 1316396807 · SAN MARCOS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,218 in 49 payments from 16 companies in 2025. Trend: 2023 $723 · 2024 $1,059 · 2025 $1,218
Food & beverage: $1,218
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 17 | $304 |
| GENZYME CORPORATION | 6 | $212 |
| Regeneron Healthcare Solutions, Inc. | 1 | $118 |
| Novartis Pharmaceuticals Corporation | 4 | $85 |
| Pharming Healthcare, Inc. | 3 | $71 |
| CSL Behring | 3 | $68 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $63 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $60 |
| Grifols USA, LLC | 2 | $48 |
| Octapharma USA, Inc. | 1 | $37 |
Products named: NUCALA, DUPIXENT, TRELEGY ELLIPTA, RUCONEST, NEFFY, Xembify, Hizentra, PANZYGA.
Industry payments across CA — which companies pay providers there.
